News

Treatment with nipocalimab led to significant reductions in disease severity among people with generalized myasthenia gravis (gMG), as assessed by a drop in the MG Activities of Daily Living (MG-ADL) score, according to top-line data from a pivotal Phase 3 trial. Findings from the trial, dubbed VIVACITY-MG3…

Treatment with the investigational CAR T-cell therapy Descartes-08 led to deep and sustained reductions in disease severity among generalized myasthenia gravis (gMG) patients, according to top-line data from a Phase 2b clinical trial. The therapy, designed somewhat differently than others in its class, also avoided some of the potentially…

Harbour BioMed has submitted a new, revised version of a biologics license application (BLA) to China’s regulatory agency requesting the approval of batoclimab (HBM9161) to treat generalized myasthenia gravis (MG). The original application was accepted for review last year by China’s National Medical Products Administration (NMPA). The…

Patients who received Vyvgart (efgartigimod alfa) as part of an expanded access program required more frequent dosing to treat generalized myasthenia gravis (gMG) than what was used during clinical testing, according to a small study in the Netherlands. Study findings also showed that more than half of the…

People with myasthenia gravis (MG) who have more active disease are at a higher risk of having an exacerbation, or a sudden worsening of symptoms, a new study from Germany has found. Even after appropriate treatment for an exacerbation, this group of MG patients remained clinically more impaired, the…

Treatment with Keytruda (pembrolizumab), an immune checkpoint inhibitor (ICI) used to treat cancer, may trigger myasthenia gravis (MG), according to a recent case report. The patient, a 73-year-old man with a previous history of skin and prostate cancer, developed symptoms of MG and myositis — a disease in which…

The Myasthenia Gravis Foundation of America (MGFA) is introducing a helpline to assist those living with myasthenia gravis (MG) and their caregivers understand and cope with the autoimmune neuromuscular disorder. The helpline — 1-833-647-8764 (1-833-MGSTRNG) — is initially open from 9 a.m. to 8 p.m. EST Monday through…

NMD Pharma announced the dosing of the first patient in a Phase 2b clinical trial of NMD670, its investigational oral therapy for generalized myasthenia gravis (gMG). The SYNAPSE-MG trial (NCT06414954), recently cleared by the U.S. Food and Drug Administration (FDA), is assessing the treatment’s safety and…

A greater reduction in disease severity a month after surgery to remove the thymus gland in myasthenia gravis (MG) patients without a thymus tumor is linked with lower disease recurrence, a study in China suggests. Patients with a reduction of at least 36.7% in the Quantitative Myasthenia Gravis score…

Blood levels of interleukin-41 (IL-41) — a signaling molecule involved in immune responses — are found to be significantly elevated in people with myasthenia gravis (MG), and associated with disease severity and inflammatory markers, a study from China reports. These findings indicate “IL-41 may be essential to the [disease]…